Oconee Memorial Hospital
- Type
- Teaching hospital
- Where
- Seneca, SC
- Medicare CCN
- 420009
- Received
- $303,055 in 88 records, 2020 ($77,336 general, $225,719 research)
- Source
- CMS Open Payments search ↗
On this site
- Federal award recipient: OCONEE MEMORIAL HOSPITAL INC Fuzzy (name and state)
- Lobbying client: OCONEE MEMORIAL HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 25 | $77,336 |
| 2020 | Research payment | 63 | $225,719 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| Boston Scientific Corporation | 14 | $76,264 | 2020 |
| Abbott Laboratories | 8 | $60,449 | 2020 |
| Smith+Nephew, Inc. | 3 | $56,230 | 2020 |
| AstraZeneca Pharmaceuticals LP | 9 | $34,202 | 2020 |
| Janssen Research & Development, LLC | 7 | $20,918 | 2020 |
| Inari Medical, Inc. | 12 | $19,262 | 2020 |
| AstraZeneca UK Limited | 3 | $8,472 | 2020 |
| Cook Research Incorporated | 11 | $7,096 | 2020 |
| Vapotherm Inc | 11 | $6,419 | 2020 |
| Linvatec Corporation | 2 | $4,520 | 2020 |
| Acerta Pharma LLC | 2 | $3,702 | 2020 |
| Globus Medical, Inc. | 1 | $2,307 | 2020 |
| Ipsen Bioscience Inc. | 1 | $1,063 | 2020 |
| Novo Nordisk Inc | 1 | $1,000 | 2020 |
| LANTHEUS MEDICAL IMAGING, INC. | 1 | $852 | 2020 |
| GE HEALTHCARE | 1 | $206 | 2020 |
| Verastem, Inc. | 1 | $90 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 63 | $225,719 |
| Grant | 6 | $62,827 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 11 | $6,419 |
| Space rental or facility fees (teaching hospital only) | 5 | $5,800 |
| Gift | 2 | $2,082 |
| Charitable Contribution | 1 | $206 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $3,303 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | MEDI4736 anti-PD-L1 mab Solid Tumor-MEDI4736 Ph2 Gastr (Treme combo vs mono) | 2020 |
| 2020-12-31 | Linvatec Corporation | $1,254 | Grant | In-kind items and services | KNEE MANUAL INSTRUMENTS Device, ORTHOPEDIC SURGERY | 2020 | |
| 2020-12-31 | Acerta Pharma LLC | $200 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2020 |
| 2020-12-31 | AstraZeneca UK Limited | $163 | Research payment | In-kind items and services | This is an open label non randomised study designed to provide continued access to AZD1775 for eligible patients with ad | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $90 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresect | 2020 |
| 2020-12-28 | Janssen Research & Development, LLC | $800 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Lo | 2020 | |
| 2020-12-21 | Boston Scientific Corporation | $1,306 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE IV | 2020 |
| 2020-12-21 | Boston Scientific Corporation | $1,288 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | RANGER II SFA | 2020 |
| 2020-12-21 | Boston Scientific Corporation | $1,182 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE IV | 2020 |
| 2020-12-21 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE IV | 2020 |
| 2020-12-21 | Cook Research Incorporated | $35 | Research payment | Cash or cash equivalent | (13-003) A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Fema | 2020 | |
| 2020-12-21 | Cook Research Incorporated | $5 | Research payment | Cash or cash equivalent | (13-003) A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Fema | 2020 | |
| 2020-12-17 | Cook Research Incorporated | $750 | Research payment | Cash or cash equivalent | Cook Medical Self-Expanding Stent Device, Peripheral Intervention | (12-004) Zilver PTX V Post Market Study in the US | 2020 |
| 2020-12-17 | Cook Research Incorporated | $290 | Research payment | Cash or cash equivalent | Cook Medical Self-Expanding Stent Device, Peripheral Intervention | (12-004) Zilver PTX V Post Market Study in the US | 2020 |
| 2020-12-11 | Janssen Research & Development, LLC | $180 | Research payment | Cash or cash equivalent | A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with | 2020 | |
| 2020-11-29 | Smith+Nephew, Inc. | $1,230 | Gift | In-kind items and services | Camera Heads Device, Sports Med Visualization | 2020 | |
| 2020-11-23 | Janssen Research & Development, LLC | $3,788 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Lo | 2020 | |
| 2020-11-16 | Boston Scientific Corporation | $42,368 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE IV | 2020 |
| 2020-11-11 | Abbott Laboratories | $29,789 | Research payment | Cash or cash equivalent | Dragonfly OPTIS optical coherence tomography (OCT) Device, Vascular | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2020 |
| 2020-11-11 | Abbott Laboratories | $7,284 | Research payment | Cash or cash equivalent | OPTIS System Device, Vascular | Validation of OCT-based FUSION Study | 2020 |
| 2020-10-27 | Smith+Nephew, Inc. | $45,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-10-15 | Abbott Laboratories | $2,400 | Research payment | Cash or cash equivalent | Dragonfly OPTIS optical coherence tomography (OCT) Device, Cardiac Arrhythmias and Heart Failure | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2020 |
| 2020-10-15 | Abbott Laboratories | $1,000 | Research payment | Cash or cash equivalent | Dragonfly OPTIS optical coherence tomography (OCT) Device, Cardiac Arrhythmias and Heart Failure | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2020 |
| 2020-10-01 | Abbott Laboratories | $6,100 | Research payment | Cash or cash equivalent | OPTIS System Device, Cardiac Arrhythmias and Heart Failure | Validation of OCT-based FUSION Study | 2020 |
| 2020-09-30 | Inari Medical, Inc. | $3,582 | Research payment | Cash or cash equivalent | ClotTriever Device, Venous Thrombectomy | ClotTriever Outcomes (CLOUT) Registry | 2020 |
| 2020-09-30 | Inari Medical, Inc. | $1,038 | Research payment | Cash or cash equivalent | ClotTriever Device, Venous Thrombectomy | ClotTriever Outcomes (CLOUT) Registry | 2020 |
| 2020-09-23 | Cook Research Incorporated | $750 | Research payment | Cash or cash equivalent | Cook Medical Self-Expanding Stent Device, Peripheral Intervention | (12-004) Zilver PTX V Post Market Study in the US | 2020 |
| 2020-09-23 | Cook Research Incorporated | $290 | Research payment | Cash or cash equivalent | Cook Medical Self-Expanding Stent Device, Peripheral Intervention | (12-004) Zilver PTX V Post Market Study in the US | 2020 |
| 2020-09-21 | Janssen Research & Development, LLC | $1,250 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Lo | 2020 | |
| 2020-09-21 | Janssen Research & Development, LLC | $1,250 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Lo | 2020 | |
| 2020-09-17 | Abbott Laboratories | $9,675 | Research payment | Cash or cash equivalent | ABT NG DES 48 EECSS Device, Cardiac Arrhythmias and Heart Failure | Abbott Next Generation Drug Eluting Stent 48mm Study (SPIRIT 48) | 2020 |
| 2020-09-17 | Abbott Laboratories | $3,300 | Research payment | Cash or cash equivalent | Dragonfly OPTIS optical coherence tomography (OCT) Device, Cardiac Arrhythmias and Heart Failure | Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized | 2020 |
| 2020-09-17 | Linvatec Corporation | $3,265 | Grant | In-kind items and services | ABC HANDPIECES Device, GENERAL SURGERY | 2020 | |
| 2020-09-08 | Boston Scientific Corporation | $2,577 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | RANGER II SFA | 2020 |
| 2020-08-17 | Boston Scientific Corporation | $9,877 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE IV | 2020 |
| 2020-08-17 | Boston Scientific Corporation | $2,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE IV | 2020 |
| 2020-07-27 | AstraZeneca Pharmaceuticals LP | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BYDUREON Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-07-21 | AstraZeneca UK Limited | $5,428 | Research payment | Cash or cash equivalent | FARXIGA Drug, Cardiovascular and Metabolism | A trial of patients aged 10 to 24 years with type 2 diabetes mellitus to evaluate the comparative efficacy and safety be | 2020 |
| 2020-07-13 | AstraZeneca Pharmaceuticals LP | $9,966 | Research payment | Cash or cash equivalent | To assess safety and tolerability describe the dose limiting toxicities determine the maximum tolerated dose MTD or the | 2020 | |
| 2020-06-30 | Inari Medical, Inc. | $2,582 | Research payment | Cash or cash equivalent | ClotTriever Device, Venous Thrombectomy | ClotTriever Outcomes (CLOUT) Registry | 2020 |
| 2020-06-30 | Inari Medical, Inc. | $2,582 | Research payment | Cash or cash equivalent | ClotTriever Device, Venous Thrombectomy | ClotTriever Outcomes (CLOUT) Registry | 2020 |
| 2020-06-30 | Inari Medical, Inc. | $1,038 | Research payment | Cash or cash equivalent | ClotTriever Device, Venous Thrombectomy | ClotTriever Outcomes (CLOUT) Registry | 2020 |
| 2020-06-30 | Inari Medical, Inc. | $518 | Research payment | Cash or cash equivalent | ClotTriever Device, Venous Thrombectomy | ClotTriever Outcomes (CLOUT) Registry | 2020 |
| 2020-06-18 | Cook Research Incorporated | $790 | Research payment | Cash or cash equivalent | (13-003) A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Fema | 2020 | |
| 2020-06-08 | Boston Scientific Corporation | $1,288 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | RANGER II SFA | 2020 |
| 2020-06-04 | Verastem, Inc. | $90 | Research payment | Cash or cash equivalent | Copiktra Drug, Hematology and Oncology | VS-0145-229 | 2020 |
| 2020-06-03 | Vapotherm Inc | $789 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Precision Flow Device, Respiratory | 2020 | |
| 2020-06-03 | Vapotherm Inc | $789 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Precision Flow Device, Respiratory | 2020 | |
| 2020-06-03 | Vapotherm Inc | $624 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Precision Flow Device, Respiratory | 2020 | |
| 2020-06-03 | Vapotherm Inc | $624 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Precision Flow Device, Respiratory | 2020 | |
| 2020-06-03 | Vapotherm Inc | $624 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Precision Flow Device, Respiratory | 2020 | |
| 2020-06-03 | Vapotherm Inc | $624 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Precision Flow Device, Respiratory | 2020 | |
| 2020-06-03 | Vapotherm Inc | $624 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Precision Flow Device, Respiratory | 2020 | |
| 2020-06-03 | Vapotherm Inc | $624 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Precision Flow Device, Respiratory | 2020 | |
| 2020-06-03 | Vapotherm Inc | $364 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Precision Flow Device, Respiratory | 2020 | |
| 2020-06-03 | Vapotherm Inc | $364 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Precision Flow Device, Respiratory | 2020 | |
| 2020-06-03 | Vapotherm Inc | $364 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Precision Flow Device, Respiratory | 2020 | |
| 2020-05-18 | Boston Scientific Corporation | $809 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE IV | 2020 |
| 2020-05-11 | AstraZeneca Pharmaceuticals LP | $6,614 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase 1, 2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Soli | 2020 |
| 2020-04-15 | Ipsen Bioscience Inc. | $1,063 | Research payment | Cash or cash equivalent | ONIVYDE Drug, Oncology | RESILIENT A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection ONIVYDE Versus Topotecan in Patients W | 2020 |
| 2020-04-09 | AstraZeneca UK Limited | $2,880 | Research payment | Cash or cash equivalent | This is an open label non randomised study designed to provide continued access to AZD1775 for eligible patients with ad | 2020 | |
| 2020-04-07 | Boston Scientific Corporation | $1,000 | Grant | Cash or cash equivalent | GENERAL - STRUCTURAL HEART Device, STRUCTURAL HEART | 2020 | |
| 2020-04-06 | Novo Nordisk Inc | $1,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-04-02 | Janssen Research & Development, LLC | $1,250 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Lo | 2020 | |
| 2020-03-31 | Inari Medical, Inc. | $2,064 | Research payment | Cash or cash equivalent | ClotTriever Device, Venous Thrombectomy | ClotTriever Outcomes (CLOUT) Registry | 2020 |
| 2020-03-31 | Inari Medical, Inc. | $1,038 | Research payment | Cash or cash equivalent | ClotTriever Device, Venous Thrombectomy | ClotTriever Outcomes (CLOUT) Registry | 2020 |
| 2020-03-31 | Inari Medical, Inc. | $1,038 | Research payment | Cash or cash equivalent | ClotTriever Device, Venous Thrombectomy | ClotTriever Outcomes (CLOUT) Registry | 2020 |
| 2020-03-24 | Acerta Pharma LLC | $3,502 | Research payment | Cash or cash equivalent | CALQUENCE Drug, Oncology | A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreat | 2020 |
| 2020-03-17 | Inari Medical, Inc. | $450 | Research payment | Cash or cash equivalent | ClotTriever Device, Venous Thrombectomy | ClotTriever Outcomes (CLOUT) Registry | 2020 |
| 2020-03-16 | Cook Research Incorporated | $2,006 | Research payment | Cash or cash equivalent | (13-003) A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Fema | 2020 | |
| 2020-03-16 | Cook Research Incorporated | $980 | Research payment | Cash or cash equivalent | (13-003) A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Fema | 2020 | |
| 2020-03-13 | LANTHEUS MEDICAL IMAGING, INC. | $852 | Gift | Cash or cash equivalent | DEFINITY Drug, CONTRAST AGENT | 2020 | |
| 2020-03-10 | Cook Research Incorporated | $450 | Research payment | Cash or cash equivalent | Cook Medical Self-Expanding Stent Device, Peripheral Intervention | (12-004) Zilver PTX V Post Market Study in the US | 2020 |
| 2020-03-06 | Janssen Research & Development, LLC | $12,400 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Lo | 2020 | |
| 2020-02-25 | Globus Medical, Inc. | $2,307 | Grant | Cash or cash equivalent | Spine Device, Spine | 2020 | |
| 2020-02-25 | AstraZeneca Pharmaceuticals LP | $900 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BYDUREON Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-02-19 | Boston Scientific Corporation | $9,315 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE IV | 2020 |
| 2020-02-19 | Boston Scientific Corporation | $2,000 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | REPRISE IV | 2020 |
| 2020-02-13 | Inari Medical, Inc. | $750 | Research payment | Cash or cash equivalent | ClotTriever Device, Venous Thrombectomy | ClotTriever Outcomes (CLOUT) Registry | 2020 |
| 2020-01-31 | Cook Research Incorporated | $750 | Research payment | Cash or cash equivalent | (13-003) A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR with Placebo in Fema | 2020 | |
| 2020-01-29 | AstraZeneca Pharmaceuticals LP | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | BYDUREON Drug, Cardiovascular and Metabolism | 2020 | |
| 2020-01-29 | Abbott Laboratories | $900 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Cardiovascular-Research only Device, Cardiac Arrhythmias and Heart Failure | 2020 | |
| 2020-01-27 | AstraZeneca Pharmaceuticals LP | $9,908 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | MEDI4736 anti-PD-L1 mab Solid Tumor-MEDI4736 Ph2 Gastr (Treme combo vs mono) | 2020 |
| 2020-01-24 | Smith+Nephew, Inc. | $10,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-01-21 | Boston Scientific Corporation | $250 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | RANGER II SFA | 2020 |
| 2020-01-15 | AstraZeneca Pharmaceuticals LP | $418 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresect | 2020 |
| 2020-01-15 | GE HEALTHCARE | $206 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-01-11 | Inari Medical, Inc. | $2,582 | Research payment | Cash or cash equivalent | ClotTriever Device, Venous Thrombectomy | ClotTriever Outcomes (CLOUT) Registry | 2020 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Seneca, SC, county Oconee County, SC, state South Carolina; placed by its city name.
| Measure | Place (city or town) Seneca, SC | County Oconee County, SC | State South Carolina |
|---|---|---|---|
| Population B01003 | 8,993 | 80,469 | 5,296,225 |
| Population, 2020 census P1 | 8,850 | 78,607 | 5,118,425 |
| Median age B01002 | 39.6 | 47.3 | 40.2 |
| Under 18 B01001 | 18.5% | 19.1% | 21.4% |
| 65 and over B01001 | 20.4% | 24.9% | 18.9% |
| Households B11001 | 4,082 | 34,515 | 2,117,989 |
| Foreign born B05002 | 2.6% | 4.2% | 5.8% |
| Median household income B19013 | $52,022 | $62,388 | $69,324 |
| Median family income B19113 | $74,864 | $80,443 | $86,707 |
| Per capita income B19301 | $34,204 | $39,360 | $39,236 |
| Poverty rate B17001 | 22.1% | 17.6% | 14.1% |
| Unemployment rate B23025 | 8.9% | 5.9% | 4.9% |
| Civilian labor force B23025 | 4,606 | 35,647 | 2,560,429 |
| Mean commute (minutes) B08013 | 16.0 | 23.9 | 25.6 |
| Bachelor's degree or higher B15003 | 29.1% | 28.7% | 32.1% |
| Housing units B25001 | 4,648 | 42,100 | 2,443,039 |
| Owner-occupied B25003 | 51.4% | 76.2% | 71.9% |
| Renters B25003 | 48.6% | 23.8% | 28.1% |
| Median home value B25077 | $240,000 | $237,100 | $259,000 |
| Median gross rent B25064 | $807 | $881 | $1,180 |
| White, not Hispanic B03002 | 72.8% | 83.1% | 61.9% |
| Black B03002 | 17.4% | 5.2% | 24.6% |
| Hispanic or Latino B03002 | 6.4% | 6.2% | 7.4% |
| Asian B03002 | 0.8% | 0.7% | 1.7% |
| American Indian and Alaska Native B03002 | 0.8% | 0.4% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Seneca, SC.
Comments